1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties

Patent metadata

Field	Value
Publication number	US-9849138-B2
Application number	US-201514846478-A
Country	US
Kind code	B2
Filing date	Sep 4, 2015
Priority date	Nov 17, 2009
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.

First claim

I claim:

1. A method of treating a fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof;
wherein R 2 is selected from the group consisting of H, alkyl, and substituted alkyl;
wherein R 3 is selected from the group consisting of H; alkyl; and OH;
wherein R 4 is N;
wherein R 5 is selected from the group consisting of H, alkyl, substituted alkyl, mono-substituted aryl, di-substituted aryl, and tri-substituted aryl;
wherein R 6 is N;
wherein R 7 , R 8 , R 9 , and R 10 are independently absent or are selected from the group consisting of —H, halogen, —CF 3 ,

—OH, fluoroalkyl, —SO 2 R 28 , —SO 2 N(R 7′ ) 2 , —OR 7′ , —N(R 7′ ) 2 , —CON(R 7′ ) 2 , —NHCOR 7′ , —NHSO 2 R 7′ , alkyl, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl; wherein R 7′ is selected from the group consisting of halogen, H, alkyl, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl, aryl, mono-substituted aryl, di-substituted aryl, tri-substituted aryl, cycloaliphatic, mono-substituted cycloaliphatic, di-substituted cycloaliphatic, and tri-substituted cycloaliphatic;
wherein R 15 , R 16 , R 17 , and R 18 are C;
wherein R 25 , R 26 , R 27 , and R 28 are independently selected from the group consisting of hydrogen, alkyl,

wherein no more than three of R 25 , R 26 , R 27 , and R 28 can be hydrogen;
wherein the stereochemical configuration at a stereocenter in the compound is R, S, or a mixture thereof;
wherein each substituted alkyl, substituted cycloaliphatic, or substituted aryl independently has at least one of the hydrogen atoms replaced by a halogen, an amino, a hydroxy, a nitro, a lower aliphatic, an aryl, or a cycloaliphatic; and
wherein the fibrosis is located in one or more of the subject's hands, intestines, joints, lungs, liver, heart, and skin.

2. The method of claim 1 , wherein the compound is described by a formula selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the fibrosis is associated with a disorder selected from the group consisting of Dupuytren's contracture, Crohn's disease, degenerative joint disease, pulmonary fibrosis, cirrhosis, a myocardial infarction, and scleroderma.

4. The method of claim 1 , wherein the subject is a human patient.

5. The method of claim 4 , wherein the fibrosis is located in the patient's lungs.

6. The method of claim 5 , wherein the fibrosis is pulmonary fibrosis.

7. The method of claim 4 , wherein the fibrosis is located in the patient's liver.

8. The method of claim 7 , wherein the fibrosis is cirrhosis.

Assignees

• Univ Michigan Regents

Inventors

• Glick Gary D

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title